About CymaBay Therapeutics
CymaBay Therapeutics is a company based in Hayward (United States) founded in 1991 was acquired by Gilead in February 2024. CymaBay Therapeutics has raised $276.71 million across 18 funding rounds from investors including Gilead, SVB and AllianceBernstein. CymaBay Therapeutics offers products and services including Antiviral Medicines and Oncology Drugs. CymaBay Therapeutics operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Madrigal Pharmaceuticals, among others.
- Headquarter Hayward, United States
- Stage Public
- SectorsHealthcare
- Website cymabay.com
- Social LinkedIn YouTube
- Acquired by Gilead (Feb 2024)
- Legal Name Gilead Sciences, Inc.
Products & Services of CymaBay Therapeutics
CymaBay Therapeutics offers a comprehensive portfolio of products and services, including Antiviral Medicines and Oncology Drugs.
Treatments for viral diseases like HIV and hepatitis
Medications for cancer and related conditions
Apps and channels of CymaBay Therapeutics
its YouTube channel Gilead Sciences has 5.9K subscribers and 30 videos.
Videos from CymaBay Therapeutics
The most watched videos on CymaBay Therapeutics's YouTube channel, Gilead Sciences (5.9K subscribers). Click a video to play it here.
More on Gilead Sciences.
Funding Insights of CymaBay Therapeutics
CymaBay Therapeutics has successfully raised a total of $276.71M across 18 strategic funding rounds. The most recent funding activity was a Grant round of $100 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $276.71M
- Total Rounds 18
- Last Round Grant — $100M
- First Round $33.5M
(Jul 1997)
- Investors Count 25
Latest 10 of 18 funding rounds of CymaBay Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2021 | $100M | Grant | – | – | |
| Jan 2018 | $5M | Post-IPO | – | – | |
| Aug 2015 | $324,999 | Unspecified | – | – | – |
| Dec 2013 | $5M | Debt – Venture | – | – | |
| Oct 2013 | $38M | Series E | – | – | – |
| Oct 2013 | $32.76M | Series D | – | – | – |
| Apr 2010 | $156,250 | Grant | – | – | |
| Nov 2009 | $8.6M | Series D | – | KBC Private Equity, Pictet Group | |
| Jul 2009 | $27.75M | Series D | – | – | – |
| Mar 2008 | $21M | Series D | – | – | – |
26 investors in total: 26 institutional.
Investors in CymaBay Therapeutics
CymaBay Therapeutics has secured backing from 26 investors, including venture fund and institutional investors. Prominent investors backing the company include Gilead, SVB and AllianceBernstein.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Venture capital firm focused on healthcare companies | – | altapartners.com | Jackson, United States | |
Venture capital firm focused on tech sectors | – | venrock.com | Palo Alto, United States | |
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | – | versantventures.com | - | |
Stage-agnostic investments in US life-sciences sectors are managed. | – | baycitycapital.com | San Francisco, United States | |
Venture capital firm | – | vpcp.com | Santa Barbara, United States | |
PE firm focusing on seed and early stage companies based out of Belgium | – | kbcpe.be | Brussels, Belgium | |
- | – | charterls.com | - | |
Biotechnology investments are targeted by the venture capital firm. | – | merlinbiomed.com | New York, United States |
Investor details for CymaBay Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CymaBay Therapeutics
17 people are tracked at CymaBay Therapeutics (7 in leadership, 1 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Robert Martin | Senior Vice President, Manufacturing and Nonclinical Development | Leadership |
Klara Dickinson | Chief Regulatory and Quality Assurance Officer | Leadership |
Ken B. | Senior Vice President Human Resources | Leadership |
Shweta G. | Director Of Operations | Leadership |
Patricia Rohane | Vice President, Clinical Development | Leadership |
Ada Lee | Sr Director, Clinical Development | Leadership |
Susheela Carroll | Senior Director Of Clinical Development | Leadership |
Thomas G. Wiggans | Director | Board & advisors |
Larisa P. | R&d Accounting Manager | Team |
Ji Young Seo | Accounting Manager | Team |
William Hahne | Medical Consultant | Team |
Georgina Xanthou | Senior Medical Writer | Team |
Erica Pedagat | Clinical Research Associate | Team |
Paul Quinlan | General Counsel and Secretary | Team |
Akash Patnaik | Corporate Controller | Team |
James Miller | Quality Assurance (qa) Manager | Team |
Claudia Koontz | Sr. Clinical Trial Manager | Team |
Complete people profiles for CymaBay Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CymaBay Therapeutics
5 dated milestones of CymaBay Therapeutics across 33 years, from founding to its latest funding, stage changes and deals.
- Founded CymaBay Therapeutics is founded.
- Funding First funding round of $33.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $100.0M.
- Exit Acquired by Gilead.
Competitors of CymaBay Therapeutics
CymaBay Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Madrigal Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. | |
| mirumpharma.com | 2018 | Menlo Park, United States | $120M | 196 | Small molecule therapeutics are developed for rare diseases treatment. | |
| madrigalpharma.com | 2011 | Conshohocken, United States | $38.38M | 56 | Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis | |
| akerotx.com | 2017 | San Francisco, United States | $135M | 33 | Small molecule therapeutics for metabolic disorders are developed. | |
| ternspharma.com | 2017 | San Mateo, United States | $207.7M | 46 | Therapies for liver disease and cancer are developed. | |
| enyopharma.com | 2014 | Lyon, France | $120.34M | – | Therapeutics are developed for diseases with impaired kidney function. | |
| drug-farm.com | 2015 | Shanghai, China | $83M | – | Developer of a novel treatment for metabolic diseases |
Detailed competitors of CymaBay Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CymaBay Therapeutics
Websites that share an audience with CymaBay Therapeutics (cymabay.com).
Websites whose visitors overlap most with CymaBay Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| catalystbiosciences.com | 100% | 2.3K | #7,441,172 | View details | |
ukmi.nhs.uk | ukmi.nhs.uk | 71% | – | #6,399,462 | – |
Latest news on Cymabay Therapeutics
Complete news archive for CymaBay Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to CymaBay Therapeutics
10 companies that operate in the same segment as CymaBay Therapeutics (Metabolic Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | – | USD 761.41 M | 500 | |
Developer of therapies for the treatment of endocrine-related diseases and cancers | 2008 | San Diego, California, United States | USD 103.5 M | USD 1.04 M | 437 | |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | 2009 | Cambridge, Massachusetts, United States | USD 685 M | – | 81 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Solutions for biomarker discovery and diagnostic testing are provided. | 2000 | Morrisville, United States | USD 165.87 M | – | – | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CymaBay Therapeutics
CymaBay Therapeutics was founded in 1991 and raised its 1st funding round 6 years after it was founded.
CymaBay Therapeutics is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
CymaBay Therapeutics is a funded company, having raised a total of $276.71M across 18 funding rounds to date. The company's 1st funding round was a Series D of $21M, raised on Jul 1997.
Developer of therapeutics for liver and other chronic diseases. The lead product of the company is Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangiti. Other products include MBX-2982 for Diabetic Hypoglycemia and CB-001 for inflammatory disorders.
CymaBay Therapeutics's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
CymaBay Therapeutics offers Antiviral Medicines and Oncology Drugs.
CymaBay Therapeutics has 26 investors. Key investors include Gilead, SVB, AllianceBernstein, T. Rowe Price, and HHS.
CymaBay Therapeutics operates through Gilead Sciences, Inc..
Yes. CymaBay Therapeutics was acquired by Gilead in February 2024.